Global EMG Biosensors Market to Grow Owing to Grow to Around USD 1075 Million by 2030

The global EMG biosensors market size was worth around USD 525 million in 2021 and is predicted to grow to around USD 1075 million by 2030 with a compound annual growth rate (CAGR) of roughly 8.75% between 2022 and 2030

Electromyography refers to the diagnostic process involving the assessment of muscle health and of the nerve cells that control the muscles. EMG results are used to reveal any nerve dysfunction, problems related to nerve-to-muscle signals, or muscle dysfunctions. For muscles to contract, motor neurons transmit electrical signals. In EMG, tiny devices called electrodes are used to translate these relayed signals into graphs or data that can be further medically interpreted.

A biosensor is a medical device used to detect the presence of chemicals with the help of living organisms or biological molecules. iMotions, an integrated analytics platform that is created to execute human behavior research with extremely high validity, contains an iMotions EMG module that integrates multiple EMG devices from Shimmer and BIOPAC for flexible data collection options. iMotions is capable of monitoring EMG from multiple muscle groups present around the body simultaneously. It can also detect facial muscle movements (fEMG) in virtual reality while also creating other possibilities by pairing the iMotions application programming interface (API) or other biosensors. It is one of the most flexible software that can collect, record, and visualize live data.

Although both forms of EMG, that is surface EMG and intramuscular EMG, are both widely used, there are some limitations to using needle EMG. This process does not involve voluntarily activating muscles and will not yield accurate data in case the patient is unwilling to cooperate or in the case of paralyzed patients, children, and infants. Some of the problems related to surface EMG involve the effect of fats in recording EMG signals. As per various studies, EMG recordings are more accurate in the case of people with low-fat levels, or young people as compared to older generations.

Covid-19 has had a positive impact on the global market cap owing to the increased pressure on the healthcare sector during this duration. A lot of patients showed varied symptoms post covid-19 infection and were suffering from the after-effects of the virus. In some cases, Covid-19 left certain long-lasting neurological impacts on the infected patients that resulted in higher demand for the products.

The global EMG biosensors market is anticipated to register high growth owing to the rising prevalence of neuromuscular and neurological disorders and conditions. Muscular dystrophy which is a hereditary condition involving progressive weakening and wasting of a boy's muscles is becoming pervasive with a rate as high as 3.6 per 10,000 people. Doctors across medical centers prefer to use EMG biosensors to detect any neuromuscular disorders at the early stage as it becomes easy to treat these conditions.

The rising awareness amongst the general population to regularly track their health is another reason propelling global market growth which is aided by multiple initiatives undertaken by the government and private institutes working toward spreading information about health concerns and regular check-ups. The increasing research in neuromuscular disorders related to their treatment, symptoms, etc. may also aid global market expansion.

The data inaccuracy of wearable EMG biosensors may restrict the global market growth. The development in the field of novel EMG biosensors is expected to provide global market growth opportunities. The need for more sensitive detection of signals is anticipated to challenge global market growth

The global EMG biosensors market is segmented based on type, technique, end-user, and region.

Based on type, the global market is segmented into surface biosensors and intramuscular biosensors. Surface sensors seem to be contributing higher to the global market revenue. The success rate of any intramuscular injections ranges between 32 and 52% and the majority of people show resistance to accepting invasive medical devices.

Based on technique, the global market segments are pattern recognition and single-intensity registration. Both segments have been contributing to the global market significantly. However, there is a higher demand for pattern recognition techniques since there is a rise in the development of EMG-centered multisensory-based technologies.

Based on end-users, the global market is divided into ambulatory health clinics, hospitals & clinics, and academic & research centers. Hospitals are anticipated to lead the segmental growth. The global medical device industry stands at a market value of USD 446 billion as of 2021 and is anticipated to grow at a CAGR of 5.62% in the next five years.

The global EMG biosensors market is anticipated to be led by North America driven by factors like new product launches, technological advancements, a rise in funding for advanced and high-quality medical devices, along with increased awareness related to sensory states is expected to drive the growth of product demand in the region. The United States is projected to become the highest contributing region in North America essentially because of its excellent medical infrastructure and the high health consciousness rate of the general population.

The European market may also generate significant revenue because of exhaustive initiatives undertaken by the government to improve health monitoring in the region. There has been a constant effort toward developing a novel technique called Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles (SENIAM) under which health monitoring is expected to become a smooth process.

The global EMG biosensors market is led by players like Delsys Incorporated, iMotions, Compumedics NeuroScan, OpenBCI, Butler Technologies, EB Neuro S.p.A, Biometrics Ltd., and Ceribell Inc.

Recent Developments:

• In May 2020, Philips launched a next-generation wearable biosensor capable of early detection of patient deterioration. The process also included clinical surveillance for Covid-19 patients. The product named Philips Biosensor BX100 is created to improve ways of addressing vital signs measurements while also providing supporting surveillance for patients requiring intensive care while being moved from the Intensive Care Unit (ICU) to general case areas.
• In December 2021, the US Food and Drugs Administration approved a new treatment for Myasthenia Gravis, a type of neuromuscular disorder. The approved product is called Vyvgart and can be used on patients suffering from Myasthenia Gravis who have tested negative for acetylcholine receptor (AChR) antibody.

This review is based on a report by Zion Market Research, titled “EMG Biosensors Market By Technique (Pattern Recognition, and Single Intensity Registration), By Type (Surface biosensors, and Intramuscular Biosensors), By End-User (Ambulatory Health Clinics, Hospitals & Clinics, and Academic & Research Centers), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2030.”- Report at https://www.zionmarketresearch.com/report/emg-biosensors-market

The global EMG biosensors market is segmented as follows:

By Technique

• Pattern Recognition
• Single Intensity Registration

By Type

• Surface biosensors
• Intramuscular biosensors

By End-User

• Ambulatory Health Clinics
• Hospitals & Clinics
• Academic & Research Centers

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com